PROK · XBRL financial data

Prokidney financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (PROK's year ends in late December)

In millions of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Research and development	32	23*	27	29	31	40*	27	26	27	34*	34	36
General and administrative	14	2*	13	14	18	12*	14	14	12	11*	11	12
Total operating expenses	47	24*	40	43	49	52*	42	40	39	46*	45	49
Operating income (loss)	(47)	(24)*	(40)	(43)	(49)	(52)*	(41)	(40)	(39)	(45)*	(45)	(48)
Interest expense	0	0*	0	0	0	0*	0	0	0	0*	0	0
Income tax expense (benefit)	1	3*	0	(0)	(2)	2*	1	1	1	(2)*	0	0
Net income (loss)	(11)	(6)*	(9)	(13)	(18)	(21)*	(17)	(17)	(16)	(19)*	(20)	(28)

Fiscal quarters (PROK's year ends in late December)

In millions of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Cash and cash equivalents	191	61	84	215	108	99	98	85	95	109	102	75
Total current assets	406	374	340	450	430	396	360	324	300	281	235	190
Property and equipment, net	43	42	42	43	39	42	43	44	48	51	54	56
Right-of-use asset	3	4	6	6	6	3	3	4	4	4	3	3
Total assets	452	421	388	499	475	441	406	372	352	336	293	249
Accounts payable	4	5	3	3	3	4	3	2	2	1	3	2
Accrued liabilities	15	18	13	15	21	31	28	25	26	29	22	20
Total current liabilities	21	25	19	21	25	36	33	28	29	31	26	23
Lease liability, non-current	2	4	5	6	5	2	2	3	3	3	3	2
Total liabilities	24	29	25	27	31	39	36	33	33	35	30	26
Accumulated deficit	(1,134)	(1,140)	(1,149)	(1,162)	(1,180)	(1,201)	(1,218)	(1,234)	(1,251)	(1,270)	(1,290)	(1,318)
Total stockholders' equity	(1,093)	(1,103)	(1,096)	(972)	(980)	(995)	(999)	(1,003)	(1,008)	(1,011)	(1,024)	(884)
Total liabilities and equity	452	421	388	499	475	441	406	372	352	336	293	249

Fiscal quarters (PROK's year ends in late December)

In millions of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Net income (loss)	(11)	(6)*	(9)	(13)	(18)	(21)*	(17)	(17)	(16)	(19)*	(20)	(28)
Stock-based compensation	13*	(6)*	8	8*	7*	7*	6	7*	7*	6*	5	6*
Depreciation and amortization	1*	1*	1	1*	1*	2*	2	1*	2*	2*	2	2*
Net cash from operating activities	(24)*	(25)*	(35)	(38)*	(29)*	(24)*	(30)	(31)*	(27)*	(33)*	(42)	(40)*
Purchases of property and equipment	28*	2*	1	1*	2*	26*	1	3*	5*	6*	4	4*
Net cash from investing activities	(28)*	(96)*	58	29*	(82)*	15*	28	19*	29*	28*	35	13*
Proceeds from issuing common stock	0*	0*	—	—	4*	(0)*	—	—	7*	17*	0	0*
Share repurchases	—	year only	—	—	—	year only	—	—	—	year only	—	—
Net cash from financing activities	(0)*	(10)*	(0)	140*	4*	0*	(0)	(0)*	8*	18*	0	1*
Net change in cash	(52)*	(131)*	24	130*	(106)*	(9)*	(1)	(13)*	10*	13*	(7)	(27)*

SIC 2836 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2836 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Prokidney	75	not reported	(40)*	not reported	1.9 quarters	Q2 FY26 10-QJun 30, 2026
Parabilis Medicines	1,087	0.1	not reported	121.9M	—	Q2 FY26 10-QJun 30, 2026
Sutro Biopharma	54	9.8	(38)*	16.6M	4.3 quarters	Q2 FY26 10-QJun 30, 2026
PDS Biotechnology	5.6	not reported	(2.8)*	56.0M	2.0 quarters	Q2 FY26 10-QJun 30, 2026
iBio	56	0*	(6.2)*	64.3M	14.1 quarters	Q4 FY26 10-KJun 30, 2026
Medicinova	25	0.5	(1.9)*	49.2M	13.2 quarters	Q2 FY26 10-QJun 30, 2026
Lifevantage	15	42*	4.8*	12.5M	—	Q4 FY26 10-KJun 30, 2026
Veru	24	not reported	(5.5)*	17.1M	4.4 quarters	Q3 FY26 10-QJun 30, 2026
Avalo Therapeutics	85	not reported	(20)*	53.6M	20.0 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.